All posts by: Michael Zand

About Michael Zand

Novartis says US regulator grants speedy review of CAR-T cell therapy – Reuters

Continue reading

2017-03-30 NEWS

Reuters

Novartis says US regulator grants speedy review of CAR–T cell therapy
Reuters
The move would keep Novartis on track with the development of its so-called chimeric antigen receptor T cell therapy, or CAR-T, in partnership with University of Pennsylvania researchers. The therapy involves a patient’s own T–cells being altered in …
Novartis Makes Plans For Its Cancer-Killing T CellsForbes
Novartis Says CAR–T Cell Therapy BLA Granted FDA Priority ReviewNasdaq
Does the drama of the CAR–T race actually matter?STAT
MedCity News –Endpoints News –Healio
all 10 news articles »
Continue reading

2017-03-30 NEWS

Forbes

Novartis says US regulator grants speedy review of CAR–T cell therapy
Reuters
The move would keep Novartis on track with the development of its so-called chimeric antigen receptor T cell therapy, or CAR-T, in partnership with University of Pennsylvania researchers. The therapy involves a patient’s own T–cells being altered in …
Novartis Makes Plans For Its Cancer-Killing T CellsForbes
Novartis gets speedy review for CAR–T cell therapyPharmaTimes
Novartis Says CAR–T Cell Therapy BLA Granted FDA Priority ReviewNasdaq
pharmaphorum –STAT –MedCity News
all 15 news articles »
Continue reading

2017-03-30 NEWS

Stem cells A case of metabolic identity in the intestinal crypt
Nature.com
How does metabolism contribute to epithelial renewal in the intestinal crypt? According to a new study published in Nature, LGR5+ crypt base columnar cells (CBCs) and Paneth cells — key constituents of the intestinal stem cell niche — have different …

Continue reading

2017-03-29 NEWS

Forbes

Novartis Makes Plans For Its Cancer-Killing T Cells
Forbes
There’s a race on to be the first company to launch what’s a CAR-T — a technology that genetically alters cancer patients’ white blood cells to kill tumor cells. (It stands for chimeric antigen receptor T–cell, which means “white blood cells with …
Novartis Says CAR–T Cell Therapy BLA Granted FDA Priority ReviewNasdaq
First come, first served: Novartis finalizes CAR–T application, claims priority reviewMedCity News
Does the drama of the CAR–T race actually matter?STAT
Endpoints News –Healio
all 7 news articles »
Continue reading

2017-03-29 NEWS

Endpoints News

Novartis announces first CAR–T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted …
Yahoo Finance
CAR-T is different from typical small molecule or biologic therapies currently on the market because it is manufactured for each individual patient. During the treatment process, T cells are drawn from a patient’s blood and reprogrammed in the …
Novartis gets a speedy review for its CAR–T pioneer as FDA lines up a marketing decisionEndpoints News
Does the drama of the CAR–T race actually matter?STAT
FDA grants priority review to CTL019 for ALLHealio

all 4 news articles »